Lichen Planus Global Market Report 2025

The lichen planus market size has grown strongly in recent years. It will grow from $1.18 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be credited to increased awareness of skin-related conditions, enhanced access to medical care, a rising elderly population, the proliferation of dermatology clinics, and higher healthcare expenditures.

The lichen planus market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The projected growth in the forecast period can be attributed to increasing demand for biologic therapies, continuous clinical research into new treatment options, the expansion of teledermatology services, a heightened emphasis on personalized medicine, and the development of healthcare infrastructure in emerging regions. Key trends expected during this period include advancements in targeted biologics, the application of artificial intelligence in dermatological diagnostics, innovative drug delivery systems, the adoption of telemedicine platforms, wearable devices for skin monitoring, and the use of 3D skin imaging technologies.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the lichen planus market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy tissues. These conditions include rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The rise in autoimmune diseases is influenced by genetic predisposition, where specific gene variations affect immune system function, as well as abnormalities in connective tissues. This growing occurrence of autoimmune disorders reflects a broader issue of immune system dysregulation and is linked to a higher number of lichen planus cases. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that approximately 514,000 people or 2 percent of the population were living with rheumatoid arthritis in 2022. This condition accounted for 2 percent of the total disease burden and 16 percent of the musculoskeletal conditions burden in 2023, with 1,322 related deaths or 5.1 deaths per 100,000 people recorded in 2022, representing 0.7 percent of all deaths. Therefore, the rising prevalence of autoimmune diseases is a major factor fueling the growth of the lichen planus market.

Leading companies in the lichen planus market are focusing on the development of innovative approaches such as liposomal formulations to improve targeted drug delivery and reduce systemic side effects. Liposomal formulations are advanced drug delivery systems in which active ingredients are enclosed within liposomes, which are small spherical vesicles composed of lipid bilayers. These formulations help enhance drug stability, improve absorption, and allow for precise delivery to affected areas while minimizing exposure to the rest of the body. For example, in February 2025, Lipella Pharmaceuticals Inc., a biotechnology company based in the United States that focuses on treatments for serious diseases, received approval from the United States Food and Drug Administration for an expanded access program for LP 310. This product is a liposomal formulation of tacrolimus, created to deliver targeted relief to patients with oral lichen planus while limiting systemic exposure. The program enables patients with serious or life threatening conditions who lack alternative treatment options to access therapies outside of clinical trials prior to full regulatory approval.

In September 2024, Eli Lilly and Company, a U.S.-based pharmaceutical company, formed a partnership with EVA Pharma to improve access to baricitinib (Olumiant) in 49 low- to middle-income countries across Africa. This collaboration aims to reach approximately 20,000 patients by 2030, targeting conditions such as lichen planus, rheumatoid arthritis, alopecia areata, and atopic dermatitis. Under the agreement, Lilly will provide manufacturing expertise to help EVA Pharma locally produce and distribute the medication. EVA Pharma is an Egypt-based pharmaceutical company, specializing in the production and distribution of generic prescription medications across a wide range of therapeutic areas.

Major players in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, and Lipella Pharmaceuticals Inc.

North America was the largest region in the lichen planus market in 2024. The regions covered in lichen planus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lichen planus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lichen planus is a persistent inflammatory condition that targets the skin, mucous membranes, and occasionally the nails or hair. It is marked by the appearance of purplish, itchy, flat-topped lesions, typically seen on the wrists, ankles, and lower back. The condition can also impact the inside of the mouth, leading to white, lace-including patches or painful ulcers.

The primary forms of the disease include lichen planus, oral lichen planus, genital lichen planus, and lichen planus pigmentosus. It is a chronic autoimmune disorder in which the immune system erroneously attacks the skin and mucous membranes. Treatment options encompass topical therapies, systemic therapies, phototherapy, and alternative approaches. These therapies are administered through various routes, including topical, oral, intravenous, and intradermal methods, and are used across healthcare settings such as hospitals, homecare, specialty clinics, and other facilities.

The lichen planus market research report is one of a series of new reports that provides lichen planus market statistics, including lichen planus industry global market size, regional shares, competitors with a lichen planus market share, detailed lichen planus market segments, market trends and opportunities, and any further data you may need to thrive in the lichen planus industry. The lichen planus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lichen planus market consists of revenues earned by entities by providing services such as narrowband UVB therapy, oral hygiene counseling, and dental check-ups. The market value includes the value of related goods sold by the service provider or included within the service offering. The lichen planus market also includes sales of topical corticosteroids, systemic immunosuppressants, antihistamines, biologic therapies, phototherapy equipment, diagnostic tools, and herbal and alternative remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.